Skip to main content
Sai Parenteral's Limited logo

Sai Parenteral's Limited — Investor Relations & Filings

Ticker · SAIPARENT ISIN · INE0H9F01037 LEI · 984500ABF36AF1C83D64 BSE.NS Manufacturing
Open in API
Filings indexed 27 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS SAIPARENT

About Sai Parenteral's Limited

https://www.saiparenterals.com/

Sai Parenteral's Limited specializes in the development, manufacture, and distribution of sterile injectable formulations. The company's core operations focus on a diverse portfolio of parenteral products, including Small Volume Parenterals (SVP), Large Volume Parenterals (LVP), and cephalosporin dry powder injections. Its technical capabilities extend to liquid vials, ampoules, and lyophilized products across multiple therapeutic categories such as anti-infectives, analgesics, and critical care. Utilizing advanced manufacturing infrastructure that complies with Good Manufacturing Practices (GMP), the company provides integrated contract development and manufacturing services (CDMO) alongside its proprietary product range. The organization emphasizes high-quality aseptic processing and formulation stability to meet the requirements of global healthcare providers and institutional markets.

Recent filings

Filing Released Lang Actions
Statement on Deviation or Variation of funds
Regulatory Filings Classification · 85% confidence The document is a compliance disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulation 32 regarding the statement on deviation or variation in utilization of IPO proceeds. It is not announcing a new fundraising, nor is it a formal financial report, AGM material, director dealing, etc. It is a routine regulatory filing required by the stock exchanges, fitting the fallback category for general compliance announcements.
2026-05-23 English
Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026
Interim / Quarterly Report Classification · 92% confidence The document is the statutory outcome of the Board Meeting under SEBI LODR, containing the Board’s approval of unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 (with detailed financial statements and notes) as well as the audited financial results for the year ended 31 March 2026 and accompanying audit reports. This is more than a brief earnings announcement, and it contains full financial tables for interim periods. It is not a full Annual Report (10-K), but rather the company’s interim/quarterly filing of actual financial statements. Therefore, it should be classified as an Interim/Quarterly Report (IR). 9M 2025
2026-05-23 English
Un Audited financial results (Standalone and Consolidated) for the quarter and nine months ended 31.12.2025
Interim / Quarterly Report Classification · 94% confidence The document is a filing to the stock exchanges on outcome of the Board meeting, which includes the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, along with the limited review report and audited financial results for the year ended 31 March 2026. It contains full interim financial statements and notes, not merely a short earnings release. Therefore, it is an Interim / Quarterly Report under Regulation 33 of SEBI LODR. 9M 2025
2026-05-23 English
With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenterals Limited held on Saturday, the 23rd day of May, 2026 at 11:30 a.m. at the Registered ....
Interim / Quarterly Report Classification · 87% confidence The document is a detailed exchange filing announcing and providing actual unaudited financial statements for the quarter and nine months ended December 31, 2025 (with accompanying limited review reports) and audited results for the year ended March 31, 2026. It contains full financial line‐item disclosures, not merely a high‐level earnings summary or a short notice of report publication. Under our taxonomy, this constitutes an Interim/Quarterly Report rather than an Earnings Release or annual 10-K. Therefore, it is classified as IR (Interim/Quarterly Report). 9M 2026
2026-05-23 English
Sai Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. Un-audited financial results ....
Regulatory Filings Classification · 85% confidence The document is an intimation to stock exchanges under SEBI regulations about an upcoming Board Meeting date and agenda items (financial results and audit reports). It does not contain the actual financial statements or a report itself but is a regulatory announcement. This fits the fallback category for miscellaneous regulatory filings rather than a substantive report. Hence it should be classified as Regulatory Filings (RNS).
2026-05-19 English
Monitoring Agency Report
Regulatory Filings Classification · 98% confidence The document is a formal submission to stock exchanges by Sai Parenterals Limited attaching a Monitoring Agency Report under SEBI ICDR and LODR regulations regarding utilization of IPO proceeds for the quarter ended March 31, 2026. It is a compliance/regulatory disclosure rather than a full financial report, earnings release, board change notice, or other specific category. There is no standalone category for Monitoring Agency Reports, so it falls under the general regulatory filings (RNS) which serve as a catch-all for compliance documents.
2026-05-13 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.